JP2020528430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528430A5 JP2020528430A5 JP2020503840A JP2020503840A JP2020528430A5 JP 2020528430 A5 JP2020528430 A5 JP 2020528430A5 JP 2020503840 A JP2020503840 A JP 2020503840A JP 2020503840 A JP2020503840 A JP 2020503840A JP 2020528430 A5 JP2020528430 A5 JP 2020528430A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disorders
- obsessive
- compulsive
- dependence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 208000035475 disorder Diseases 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 34
- 150000003839 salts Chemical group 0.000 claims description 27
- 208000002193 Pain Diseases 0.000 claims description 20
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 19
- 208000020016 psychiatric disease Diseases 0.000 claims description 18
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 14
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 14
- 206010013663 drug dependence Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 201000000980 schizophrenia Diseases 0.000 claims description 12
- 208000011117 substance-related disease Diseases 0.000 claims description 12
- 208000015114 central nervous system disease Diseases 0.000 claims description 11
- 208000007848 Alcoholism Diseases 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 8
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 201000007930 alcohol dependence Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims description 8
- 201000005040 opiate dependence Diseases 0.000 claims description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 7
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 7
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 206010041250 Social phobia Diseases 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229940127240 opiate Drugs 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 4
- 206010061619 Deformity Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000012488 Opiate Overdose Diseases 0.000 claims description 4
- 206010034158 Pathological gambling Diseases 0.000 claims description 4
- 206010034912 Phobia Diseases 0.000 claims description 4
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 4
- 208000029650 alcohol withdrawal Diseases 0.000 claims description 4
- 201000006145 cocaine dependence Diseases 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 206010016256 fatigue Diseases 0.000 claims description 4
- 230000003370 grooming effect Effects 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 230000002969 morbid Effects 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 208000019899 phobic disease Diseases 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 2
- 206010012239 Delusion Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000018460 Feeding disease Diseases 0.000 claims description 2
- 208000010235 Food Addiction Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 206010020710 Hyperphagia Diseases 0.000 claims description 2
- 208000030990 Impulse-control disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 102000048266 Nociceptin Human genes 0.000 claims description 2
- 108090000622 Nociceptin Proteins 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 2
- 229960001736 buprenorphine Drugs 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000013078 crystal Substances 0.000 claims description 2
- 231100000868 delusion Toxicity 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 208000011736 mal de Debarquement Diseases 0.000 claims description 2
- 229960001797 methadone Drugs 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 2
- 229960004127 naloxone Drugs 0.000 claims description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 2
- 229960003086 naltrexone Drugs 0.000 claims description 2
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 claims description 2
- 239000004031 partial agonist Substances 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 229940076279 serotonin Drugs 0.000 claims description 2
- 230000000697 serotonin reuptake Effects 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WUZBOJXXYMKMMF-UHFFFAOYSA-N COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F Chemical compound COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F WUZBOJXXYMKMMF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537292P | 2017-07-26 | 2017-07-26 | |
| US62/537,292 | 2017-07-26 | ||
| US201862647492P | 2018-03-23 | 2018-03-23 | |
| US62/647,492 | 2018-03-23 | ||
| PCT/US2018/043102 WO2019023063A1 (en) | 2017-07-26 | 2018-07-20 | ORGANIC COMPOUNDS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528430A JP2020528430A (ja) | 2020-09-24 |
| JP2020528430A5 true JP2020528430A5 (https=) | 2021-08-26 |
| JP7224333B2 JP7224333B2 (ja) | 2023-02-17 |
Family
ID=65041284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503840A Active JP7224333B2 (ja) | 2017-07-26 | 2018-07-20 | 有機化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11427587B2 (https=) |
| EP (1) | EP3658144B1 (https=) |
| JP (1) | JP7224333B2 (https=) |
| KR (1) | KR102667268B1 (https=) |
| CN (1) | CN111093664B (https=) |
| AU (1) | AU2018307480B2 (https=) |
| CA (1) | CA3071137A1 (https=) |
| IL (1) | IL272252B2 (https=) |
| MX (1) | MX2020000967A (https=) |
| WO (1) | WO2019023063A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168219B (zh) * | 2008-05-27 | 2018-11-20 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
| WO2013155504A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| CN108883111B (zh) | 2016-01-26 | 2021-10-08 | 细胞内治疗公司 | 有机化合物 |
| PL3407889T3 (pl) | 2016-03-25 | 2021-11-22 | Intra-Cellular Therapies, Inc. | Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego |
| IL268970B2 (en) | 2017-03-24 | 2023-12-01 | Intra Cellular Therapies Inc | Oral transmucosal formulations of substituted heterocycle fused gamma carbolines |
| JP7224333B2 (ja) * | 2017-07-26 | 2023-02-17 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP7223742B2 (ja) * | 2017-07-26 | 2023-02-16 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| CN111107847A (zh) | 2017-09-26 | 2020-05-05 | 细胞内治疗公司 | 新的盐和晶体 |
| WO2019178484A1 (en) | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| AU2019240226B2 (en) | 2018-03-23 | 2024-11-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| BR112021011792A2 (pt) | 2018-12-17 | 2021-08-31 | Intra-Cellular Therapies, Inc. | Composto orgânico |
| IL283963B2 (en) | 2018-12-17 | 2025-01-01 | Intra Cellular Therapies Inc | Synthesis of condensed gamma-carbolines and converted heterocycles |
| EP3898580A4 (en) * | 2018-12-17 | 2022-08-10 | Intra-Cellular Therapies, Inc. | SYNTHESIS OF CONDENSED GAMMA-CARBOLINES WITH SUBSTITUTED HETEROCYCLE |
| US12195463B2 (en) | 2018-12-21 | 2025-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2020132605A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN118105390A (zh) * | 2019-01-23 | 2024-05-31 | 细胞内治疗公司 | 治疗成瘾的方法 |
| EP3946345A4 (en) * | 2019-04-04 | 2023-01-04 | Intra-Cellular Therapies, Inc. | METHODS OF TREATMENT OF NEUROPATHIC PAIN |
| JP7673040B2 (ja) | 2019-07-07 | 2025-05-08 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| EP4034119A4 (en) * | 2019-09-25 | 2023-10-18 | Intra-Cellular Therapies, Inc. | NOVEL METHODS |
| EP4072554A4 (en) | 2019-12-11 | 2023-12-20 | Intra-Cellular Therapies, Inc. | ORGANIC CONNECTION |
| EP4493560A4 (en) * | 2022-03-14 | 2026-03-18 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| US20260014247A1 (en) | 2022-07-12 | 2026-01-15 | Sk Bioscience Co., Ltd. | Sars-cov-2 vaccine booster composition |
| JP2026502895A (ja) | 2022-12-30 | 2026-01-27 | イントラ－セルラー・セラピーズ・インコーポレイテッド | セロトニン５－ｈｔ２ａ受容体に作用する複素環縮合ガンマ－カルボリン |
| EP4665344A1 (en) | 2023-02-17 | 2025-12-24 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
| WO2025257090A1 (en) | 2024-06-10 | 2025-12-18 | Interquim, S.A. | Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues |
| WO2026011166A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor |
| WO2026011136A1 (en) | 2024-07-03 | 2026-01-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2490813A (en) | 1944-11-29 | 1949-12-13 | Standard Oil Co | Continuous process for making aryl amines |
| US3299078A (en) | 1962-10-01 | 1967-01-17 | Smith Kline French Lab | Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines |
| US3813392A (en) | 1969-06-09 | 1974-05-28 | J Sellstedt | Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| IE41352B1 (en) | 1974-04-01 | 1979-12-19 | Pfizer | 5-aryl-1,2,3,4-tetrahydro- -carbolines |
| US4001263A (en) | 1974-04-01 | 1977-01-04 | Pfizer Inc. | 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines |
| US4136145A (en) | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4522944A (en) | 1982-12-23 | 1985-06-11 | Erba Farmitalia | Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use |
| CH656884A5 (de) | 1983-08-26 | 1986-07-31 | Sandoz Ag | Polyolester, deren herstellung und verwendung. |
| ES2058068T3 (es) | 1986-03-19 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazol-(3,2-a)-pirimidin-5-ona y compuestos fungicidas con contenido en dichos derivados. |
| EP0242690B1 (en) | 1986-04-07 | 1993-06-30 | Kumiai Chemical Industry Co., Ltd. | 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| IT1271352B (it) | 1993-04-08 | 1997-05-27 | Boehringer Ingelheim Italia | Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale |
| CN1074923C (zh) | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
| US5576460A (en) | 1994-07-27 | 1996-11-19 | Massachusetts Institute Of Technology | Preparation of arylamines |
| US5654482A (en) | 1996-02-29 | 1997-08-05 | Xerox Corporation | Triarylamine processes |
| US5648542A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Arylamine processes |
| US5648539A (en) | 1996-02-29 | 1997-07-15 | Xerox Corporation | Low temperature arylamine processes |
| US5847166A (en) | 1996-10-10 | 1998-12-08 | Massachusetts Institute Of Technology | Synthesis of aryl ethers |
| US5705697A (en) | 1997-01-30 | 1998-01-06 | Xerox Corporation | Arylamine processes |
| US5723669A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| US5723671A (en) | 1997-01-30 | 1998-03-03 | Xerox Corporation | Arylamine processes |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| GB2328686B (en) | 1997-08-25 | 2001-09-26 | Sankio Chemical Co Ltd | Method for producing arylamine |
| US6395939B1 (en) | 1997-10-06 | 2002-05-28 | Massachusetts Institute Of Technology | Diaryl ether condensation reactions |
| WO1999043643A2 (en) | 1998-02-26 | 1999-09-02 | Massachusetts Institute Of Technology | Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes |
| US6235936B1 (en) | 1998-02-26 | 2001-05-22 | Massachusetts Institute Of Technology | Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates |
| US5902901A (en) | 1998-05-07 | 1999-05-11 | Xerox Corporation | Arylamine processes |
| US6307087B1 (en) | 1998-07-10 | 2001-10-23 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| EP1097158B1 (en) | 1998-07-10 | 2006-01-25 | Massachusetts Institute Of Technology | Ligands for metals and metal-catalyzed processes |
| US7223879B2 (en) | 1998-07-10 | 2007-05-29 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| US20010008942A1 (en) | 1998-12-08 | 2001-07-19 | Buchwald Stephen L. | Synthesis of aryl ethers |
| WO2000035419A2 (en) | 1998-12-17 | 2000-06-22 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US6407092B1 (en) | 1999-04-23 | 2002-06-18 | Pharmacia & Upjohn Company | Tetracyclic azepinoindole compounds |
| PE20010052A1 (es) | 1999-04-23 | 2001-01-27 | Upjohn Co | Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| MXPA01012969A (es) | 1999-06-15 | 2003-10-14 | Bristol Myers Squibb Pharma Co | Gamma-carbolinas fusionadas de heterociclo sustituido. |
| US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
| PL366233A1 (en) | 2000-12-20 | 2005-01-24 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| US6849619B2 (en) | 2000-12-20 | 2005-02-01 | Bristol-Myers Squibb Company | Substituted pyridoindoles as serotonin agonists and antagonists |
| US6759554B2 (en) | 2001-04-24 | 2004-07-06 | Massachusetts Institute Of Technology | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds |
| US6849640B2 (en) | 2001-08-08 | 2005-02-01 | Pharmacia & Upjohn Company | Therapeutic 1H-pyrido [4,3-b] indoles |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| EP1314554A1 (fr) | 2001-11-23 | 2003-05-28 | Kba-Giori S.A. | Dispositif de décollage d'éléments de sécurité |
| US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
| KR100699516B1 (ko) | 2002-07-29 | 2007-03-26 | 알자 코포레이션 | 팔리페리돈의 조절 전달을 위한 방법 및 복용 형태 |
| KR20050032107A (ko) | 2002-08-02 | 2005-04-06 | 메사추세츠 인스티튜트 오브 테크놀로지 | 구리를 촉매로 한 탄소-헤테로원자 결합 및 탄소-탄소결합 형성방법 |
| AU2003287433A1 (en) | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| PL377426A1 (pl) | 2002-12-19 | 2006-02-06 | Bristol-Myers Squibb Company | Podstawione tricykliczne gamma-karboliny jako agoniści i antagoniści receptora serotoninowego |
| AU2004259741A1 (en) | 2003-07-21 | 2005-02-03 | Smithkline Beecham Corporation | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
| JP2005259113A (ja) | 2004-02-12 | 2005-09-22 | Ricoh Co Ltd | プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法 |
| US20080280941A1 (en) | 2004-03-05 | 2008-11-13 | Pierre Lourtie | 8-Phenoxy-Gamma Carboline Derivatives |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| AU2005286943A1 (en) | 2004-09-20 | 2006-03-30 | Mount Sinai School Of Medicine | Use of memantine (NAMENDA) to treat autism, compulsivity, and impulsivity |
| JP2008513432A (ja) | 2004-09-21 | 2008-05-01 | ファイザー・プロダクツ・インク | Ｃｎｓ状態の治療に有用なｎ−メチルヒドロキシエチルアミン |
| US7614727B2 (en) | 2004-09-30 | 2009-11-10 | Fujifilm Corporation | Liquid ejection head, manufacturing method thereof, and image forming apparatus |
| EP1824820A2 (en) | 2004-12-07 | 2007-08-29 | Janssen Pharmaceutica N.V. | Substituted tetracyclic tetrahydrofuran,pyrrolidine and tetrahydrothiophene derivatives |
| WO2006063709A1 (en) | 2004-12-15 | 2006-06-22 | F.Hoffmann-La Roche Ag | Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer’s disease |
| JP2008528514A (ja) | 2005-01-25 | 2008-07-31 | セルジーン・コーポレーション | ４−アミノ−２−（３−メチル−２，６−ジオキソピペリジン−３−イル）−イソインドール−１，３−ジオンを使用する方法及び組成物 |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| WO2007084841A2 (en) | 2006-01-13 | 2007-07-26 | Wyeth | Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors |
| KR102065319B1 (ko) | 2007-03-12 | 2020-01-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| WO2009017836A1 (en) | 2007-08-01 | 2009-02-05 | Medivation Neurology, Inc. | Methods and compositions for treating schizophrenia using antipsychotic combination therapy |
| AU2009212065B2 (en) | 2008-02-05 | 2014-03-20 | Clera Inc. | Compositions and methods for alleviating depression or improving cognition |
| JP5611846B2 (ja) | 2008-03-12 | 2014-10-22 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 置換ヘテロ環縮合ガンマ−カルボリン類固体 |
| CN105168219B (zh) | 2008-05-27 | 2018-11-20 | 细胞内治疗公司 | 用于睡眠障碍和其他疾病的方法和组合物 |
| US8309772B2 (en) | 2008-07-31 | 2012-11-13 | Celanese International Corporation | Tunable catalyst gas phase hydrogenation of carboxylic acids |
| US8927553B2 (en) * | 2009-08-10 | 2015-01-06 | Daljit Singh Dhanoa | Deuterium-enriched alkyl sulfonamides and uses thereof |
| EP2560676B8 (en) | 2010-04-22 | 2016-10-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2013155504A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| SG11201501894VA (en) | 2012-09-14 | 2015-04-29 | Abbvie Inc | Tricyclic quinoline and quinoxaline derivatives |
| HUE053159T2 (hu) * | 2013-03-15 | 2021-06-28 | Intra Cellular Therapies Inc | Szerves vegyületek |
| IL305990B2 (en) | 2013-12-03 | 2025-12-01 | Intra Cellular Therapies Inc | Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder |
| MX365969B (es) | 2014-04-04 | 2019-06-21 | Intra Cellular Therapies Inc | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. |
| RU2016143091A (ru) | 2014-04-04 | 2018-05-08 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| WO2015191554A1 (en) | 2014-06-09 | 2015-12-17 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
| CA3254279A1 (en) | 2015-06-03 | 2025-03-18 | Triastek, Inc. | PHARMACEUTICAL FORMS AND RELATED USES |
| CN108883111B (zh) | 2016-01-26 | 2021-10-08 | 细胞内治疗公司 | 有机化合物 |
| PL3407889T3 (pl) | 2016-03-25 | 2021-11-22 | Intra-Cellular Therapies, Inc. | Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego |
| US20200392135A1 (en) | 2016-03-25 | 2020-12-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
| JP2019513143A (ja) | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規塩類および結晶 |
| US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| EP4001281A1 (en) | 2016-08-09 | 2022-05-25 | Teva Pharmaceuticals International GmbH | Solid state forms of lumateperone ditosylate salt and preparation thereof |
| US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10961245B2 (en) | 2016-12-29 | 2021-03-30 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders |
| IL268970B2 (en) | 2017-03-24 | 2023-12-01 | Intra Cellular Therapies Inc | Oral transmucosal formulations of substituted heterocycle fused gamma carbolines |
| JP7224333B2 (ja) * | 2017-07-26 | 2023-02-17 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP7223742B2 (ja) | 2017-07-26 | 2023-02-16 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2019183546A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AU2019240226B2 (en) | 2018-03-23 | 2024-11-28 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| US20220160704A2 (en) | 2018-08-08 | 2022-05-26 | Torralva Medical Therapeutics Llc | Compositions for opiate and opioid prevention and reversal, and methods of their use |
| BR112021011792A2 (pt) | 2018-12-17 | 2021-08-31 | Intra-Cellular Therapies, Inc. | Composto orgânico |
| US12195463B2 (en) | 2018-12-21 | 2025-01-14 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2020132605A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3946345A4 (en) | 2019-04-04 | 2023-01-04 | Intra-Cellular Therapies, Inc. | METHODS OF TREATMENT OF NEUROPATHIC PAIN |
| CA3139168A1 (en) | 2019-05-07 | 2020-11-12 | Nirsum Laboratories, Inc. | Opioid receptor antagonist prodrugs |
-
2018
- 2018-07-20 JP JP2020503840A patent/JP7224333B2/ja active Active
- 2018-07-20 US US16/634,059 patent/US11427587B2/en active Active
- 2018-07-20 EP EP18837299.9A patent/EP3658144B1/en active Active
- 2018-07-20 AU AU2018307480A patent/AU2018307480B2/en active Active
- 2018-07-20 CN CN201880057525.5A patent/CN111093664B/zh active Active
- 2018-07-20 CA CA3071137A patent/CA3071137A1/en active Pending
- 2018-07-20 IL IL272252A patent/IL272252B2/en unknown
- 2018-07-20 WO PCT/US2018/043102 patent/WO2019023063A1/en not_active Ceased
- 2018-07-20 KR KR1020207005455A patent/KR102667268B1/ko active Active
- 2018-07-20 MX MX2020000967A patent/MX2020000967A/es unknown
-
2022
- 2022-07-19 US US17/813,473 patent/US11773095B2/en active Active
-
2023
- 2023-08-17 US US18/451,465 patent/US12173004B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528430A5 (https=) | ||
| CN111093664B (zh) | 有机化合物 | |
| RU2018130727A (ru) | Органические соединения | |
| JP2020528431A5 (https=) | ||
| JP2021519267A5 (https=) | ||
| JP3462505B2 (ja) | ８−アザビシクロ［３．２．１］オクト−２−エン誘導体、それらの製造及び使用 | |
| KR20200033307A (ko) | 유기 화합물 | |
| RU2012149633A (ru) | Органические соединения | |
| TWI661827B (zh) | 睡眠障礙之治療及預防 | |
| TWI224102B (en) | Serotonergic agents | |
| JPWO2019183341A5 (https=) | ||
| JP2002531568A (ja) | ２，５−ジアザビシクロ［２．２．１］ヘプタン誘導体、それらの製造およびそれらの治療的使用 | |
| JP7312284B2 (ja) | 重水素化デキストロメトルファンの合成方法 | |
| JPWO2020132605A5 (https=) | ||
| JP2007506709A (ja) | ヒトｏｒｌ１受容体に対するアゴニストとしてのベンズイミダゾロン及びキナゾリノン誘導体 | |
| WO2009069828A1 (ja) | パーキンソン病の運動合併症または精神症状を改善する薬剤 | |
| JPWO2020132474A5 (https=) | ||
| JP2016172717A (ja) | ニコチン性受容体非競合的アンタゴニスト | |
| JP2001507678A (ja) | 運動障害の治療のためのｎｋ−１受容体拮抗薬の使用 | |
| JP2011520987A (ja) | ニューロンｎＡＣｈＲの無痛性脱感作剤およびその使用方法 | |
| JP2001504853A (ja) | 物質使用障害の治療のためのｎｋ−１受容体拮抗薬の使用 | |
| JP2009537600A (ja) | 新規１，４−ジアザ−ビシクロ［３．２．２］ノナン誘導体及びそれらの医学的使用 | |
| US10420759B2 (en) | Small molecule therapies for pulmonary hypertension | |
| RU2761219C2 (ru) | Терапевтическое средство от расстройств, связанных с употреблением алкоголя | |
| WO2004063201A1 (ja) | 統合失調症治療剤 |